A study presented at this week’s ACR/ARHP annual congress in Washington addresses “lingering doubts” over the safety of biologics in children with JIA. The trial involved 27,621 children with JIA who were categorised into three groups: those who had used methotrexate, a TNF inhibitor, or ‘other’ medications. The researchers identified 20 incident malignancies with a ...
Biologics don’t increase cancer risks in kids with JIA
18 Nov 2016